Investment in Minnesota’s thriving medtech scene hit a 6-year high in 2014 and the state saw a significant jump in pharma/biotech investments, according to LifeScience Alley’s annual report.
Holaira said it raised a $42 million Series D round it plans to use for what it claims as the 1st randomized lung denervation trial with a sham control arm.
Minneapolis-based Holaira said the round was led by Vertex Venture Holdings and included 2 unnamed strategic investors, Windham Venture Partners and existing backers Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners and Versant Ventures.
Medical device company Holaira said it drummed up $10 million, changed its name and moved its headquarters.
Formerly known as Innovative Pulmonary Solutions, Holaira said it plans to use the Series C round to develop its minimally invasive devices to treat obstructive lung disease. All of Holaira’s existing backers participated, namely Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners, and Versant Ventures.